Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
Clearmind Medicine (Nasdaq: CMND) received a Nasdaq notice on December 4, 2025, for noncompliance with the $1.00 minimum bid price requirement after the closing bid was below $1.00 for 30 consecutive business days.
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND) received a Nasdaq notice on December 4, 2025, for noncompliance with the $1.00 minimum bid price requirement after the closing bid was below $1.00 for 30 consecutive business days.
Nasdaq granted a 180-calendar day compliance period through June 2, 2026 to regain compliance by achieving a $1.00 closing bid for at least 10 consecutive business days. The company shares will continue to be listed and traded under the symbol CMND during the period. If not compliant by June 2, 2026, the company may seek a second 180-day period only if it meets market value and other initial listing standards (except the bid-price rule). The company said it will monitor the closing bid and consider options to cure the deficiency, but provided no assurance it will regain compliance.
Positive
- Nasdaq granted a 180-day compliance period ending June 2, 2026
- Common shares will remain listed and traded on Nasdaq under CMND during the compliance period
- Company may qualify for a second 180-day compliance period if market-value criteria are met
Negative
- Closing bid was below $1.00 for 30 consecutive business days
- Must achieve $1.00 closing bid for 10 consecutive business days to regain compliance
- If noncompliant after compliance periods, Nasdaq may issue delisting notice
- Company stated there is no assurance it will regain compliance
Details
News Market Reaction – CMND
On Dec 8, the first trading day after this news, CMND closed 2.79% below the previous close.
Data tracked by StockTitan Argus for the Dec 8 session.
Key Figures
- Minimum bid price
- $1.00 per share
- Nasdaq Listing Rule 5550(a)(2) requirement
- Noncompliance period
- 30 consecutive business days
- Closing bid below $1.00 before Nasdaq notice
- Initial compliance window
- 180 calendar days
- Period to regain $1.00 minimum bid by June 2, 2026
- Required bid duration
- 10 consecutive business days
- Minimum period closing bid must be at or above $1.00
- Registered direct proceeds
- $1,297,012.76
- Gross proceeds from 7,944,868 shares and pre-funded warrants (Nov 26, 2025)
- Primary offering proceeds
- $2,185,000
- Gross proceeds from 10,925,000-share offering at $0.20 (Nov 19, 2025)
- Stockholders’ equity
- $1,065,668
- Reported level vs Nasdaq’s $2.5M minimum equity requirement
- Equity requirement
- $2.5 million
- Nasdaq minimum stockholders’ equity threshold cited in filings
Historical Context
-
First participant dosed at Hadassah site in ongoing Phase I/IIa AUD trial.
-
Positive first-cohort data, DSMB continuation, and new Tel Aviv site enrollment.
-
Tel Aviv Sourasky site fully activated with first patient enrolled for AUD trial.
-
DSMB interim review found no serious adverse events and backed trial continuation.
-
Hadassah Medical Center activated as fifth global site in AUD trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
minimum bid price requirement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, Canada, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced today that on December 4, 2025, the Company received a written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company’s closing bid price for its common shares was below
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until June 2, 2026, to regain compliance with the minimum bid price requirement. During the compliance period, the Company’s common shares will continue to be listed and traded on the Nasdaq Stock Market under the symbol “CMND”.. To regain compliance, the closing bid price of the Company’s common shares must meet or exceed
If the Company is not in compliance by June 2, 2026, the Company may be afforded a second 180-calendar day compliance period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market with the exception of the minimum bid price requirement and will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s common shares will be subject to delisting.
The Company intends to monitor the closing bid price of its common shares between now June 2, 2026, and will consider available options to resolve the Company’s noncompliance with the minimum bid price requirement as may be necessary. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses regaining compliance with Nasdaq’s continued listing requirements, and timing and effect thereof. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.